Bavarian Nordic - The sky is the limit (Seite 4)
eröffnet am 04.06.11 19:10:57 von
neuester Beitrag 17.05.24 11:15:30 von
neuester Beitrag 17.05.24 11:15:30 von
Beiträge: 2.181
ID: 1.166.681
ID: 1.166.681
Aufrufe heute: 3
Gesamt: 103.397
Gesamt: 103.397
Aktive User: 0
ISIN: DK0015998017 · WKN: 917165 · Symbol: BV3
24,065
EUR
+0,15 %
+0,035 EUR
Letzter Kurs 20:32:46 L&S Exchange
Neuigkeiten
| TitelBeiträge |
|---|
22.05.24 · globenewswire  |
21.05.24 · globenewswire |
21.05.24 · globenewswire |
08.05.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,0450 | +14.021,62 | |
| 41,20 | +101,96 | |
| 1,7870 | +28,56 | |
| 37,77 | +24,20 | |
| 6,5600 | +23,77 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 7,8165 | -26,67 | |
| 1,7000 | -31,17 | |
| 2,2850 | -32,40 | |
| 2,7350 | -38,88 | |
| 2,5300 | -68,26 |
Beitrag zu dieser Diskussion schreiben
Feedback
Und weiter geht's:
BAVARIAN NORDIC REPORTS POSITIVE PHASE 3 TOPLINE RESULTS FOR CHIKUNGUNYA VIRUS VACCINE IN ADULTS AND ADOLESCENTS
Chikungunya vaccine candidate met all the co-primary endpoints of the Phase 3 study and was shown to be highly immunogenic in the majority of subjects 22 days post a single vaccination.
A fast and durable response was confirmed with high levels of immunity at both 2 weeks and 6 months post a single vaccination.
Regulatory submissions planned for 2024
Conference call Monday, August 7 at 2 pm CEST / 8 am EDT
https://www.bavarian-nordic.com/investor/news/news.aspx?news…
BAVARIAN NORDIC REPORTS POSITIVE PHASE 3 TOPLINE RESULTS FOR CHIKUNGUNYA VIRUS VACCINE IN ADULTS AND ADOLESCENTS
Chikungunya vaccine candidate met all the co-primary endpoints of the Phase 3 study and was shown to be highly immunogenic in the majority of subjects 22 days post a single vaccination.
A fast and durable response was confirmed with high levels of immunity at both 2 weeks and 6 months post a single vaccination.
Regulatory submissions planned for 2024
Conference call Monday, August 7 at 2 pm CEST / 8 am EDT
https://www.bavarian-nordic.com/investor/news/news.aspx?news…
Antwort auf Beitrag Nr.: 74.251.710 von Nokery am 03.08.23 08:12:52As a consequence of the new order from BARDA combined with other minor mpox vaccine orders recently secured, expected savings from the discontinued RSV program and including the impact from the acquisition of the travel vaccine portfolio from Emergent BioSolutions, Bavarian Nordic upgrades its financial guidance for 2023. Revenue is now expected to be approximately DKK 6,900 million (previously approximately DKK 6,000 million) and EBITDA is now expected to be approximately DKK 2,300 million (previously approximately DKK 2,200 million). Revenue from the acquired products is only included from the date of completion of the transaction (mid-May) and is expected to be approximately DKK 165 million. The acquisition will negatively impact EBITDA by approximately DKK 375 million primarily related to the Phase 3 development of the chikungunya vaccine and one-off integration costs.
BAVARIAN NORDIC RECEIVES USD 120 MILLION CONTRACT FOR THE MANUFACTURING OF SMALLPOX AND MPOX VACCINE FROM THE U.S. GOVERNMENT
Contract award will support manufacturing of new bulk vaccine to partly replenish the inventory used for the mpox outbreak in 2022
Aims to strengthen the long-term U.S. stockpiling of smallpox vaccines
Company upgrades its financial guidance for 2023
https://www.bavarian-nordic.com/investor/news/news.aspx?news…
Contract award will support manufacturing of new bulk vaccine to partly replenish the inventory used for the mpox outbreak in 2022
Aims to strengthen the long-term U.S. stockpiling of smallpox vaccines
Company upgrades its financial guidance for 2023
https://www.bavarian-nordic.com/investor/news/news.aspx?news…
@glaube nicht dass der Boden schon gefunden wurde.....
Antwort auf Beitrag Nr.: 74.238.048 von BruderTack am 01.08.23 08:28:24Den Aktionären ca. 400 Mio. EUR nach den - 25% zu urteilen.
Trading Spotlight
Wieviel war die RSV wert? Neuer Boden scheint sich gebildet zu haben.
Also RSV ist jetzt samt entfallender Meilensteinzahlungen und etwaiger Gewinne komplett raus aus der Bewertung.
Jetzt geht es in Q3 um Chikungunya...
Jetzt geht es in Q3 um Chikungunya...
Antwort auf Beitrag Nr.: 74.193.113 von Nokery am 22.07.23 19:03:39"A continued strong growth in the Company’s travel vaccine business is expected to absorb the loss incurred from the lack of milestone payments of DKK 195 million, that are no longer expected under the Nuance partnership, and thus no impact on the financial guidance for 2023 is expected from the RSV program discontinuation."
BAVARIAN NORDIC PROVIDES UPDATE ON RSV VACCINE PROGRAM
Phase 3 study failed to meet one of the success criteria of the primary objective
RSV program to be discontinued
https://www.bavarian-nordic.com/investor/news/news.aspx?news…
Phase 3 study failed to meet one of the success criteria of the primary objective
RSV program to be discontinued
https://www.bavarian-nordic.com/investor/news/news.aspx?news…
BAVARIAN NORDIC REPORTS PHASE 3 TOPLINE RESULTS FOR ITS COVID-19 BOOSTER VACCINE CANDIDATE
Booster study successfully met its primary objective, demonstrating non-inferiority to mRNA-vaccine
Regulatory pathway will depend upon the outcome of secondary endpoints, reporting in the third quarter of 2023
https://www.bavarian-nordic.com/investor/news/news.aspx?news…
Booster study successfully met its primary objective, demonstrating non-inferiority to mRNA-vaccine
Regulatory pathway will depend upon the outcome of secondary endpoints, reporting in the third quarter of 2023
https://www.bavarian-nordic.com/investor/news/news.aspx?news…
Durchsuchen
